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Abstract
Background: The purpose of this study was to compare the effects of supplementation with Gaspari Nutrition’s
SOmaxP Maximum Performance™ (SOmaxP) versus a comparator product (CP) containing an equal amount of
creatine (4 g), carbohydrate (39 g maltodextrin), and protein (7 g whey protein hydrolysate) on muscular strength,
muscular endurance, and body composition during nine weeks of intense resistance training.
Methods: Using a prospective, randomized, double-blind design, 20 healthy men (mean ± SD age, height, weight,
% body fat: 22.9 ± 2.6 y, 178.4 ± 5.7 cm, 80.5 ± 6.6 kg, 16.6 ± 4.0%) were matched for age, body weight, resistance
training history, bench press strength, bench press endurance, and percent body fat and then randomly assigned
via the ABBA procedure to ingest 1/2 scoop (dissolved in 15 oz water) of SOmaxP or CP prior to, and another 1/2
scoop (dissolved in 15 oz water) during resistance exercise. Body composition (DEXA), muscular performance (1-RM
bench press and repetitions to failure [RTF: 3 sets × baseline body weight, 60-sec rest between sets]), and clinical
blood chemistries were measured at baseline and after nine weeks of supplementation and training. Subjects were
required to maintain their normal dietary habits and follow a specific, progressive overload resistance training
program (4-days/wk, upper body/lower body split) during the study. An intent-to-treat approach was used and
data were analyzed via ANCOVA using baseline values as the covariate. Statistical significance was set a priori at
p ≤ 0.05.
Results: When adjusted for initial differences, significant between group post-test means were noted in: 1-RM
bench press (SOmaxP: 133.3 ± 1.3 kg [19.8% increase] vs. CP: 128.5 ± 1.3 kg [15.3% increase]; p < 0.019); lean mass
(SOmaxP: 64.1 ± 0.4 kg [2.4% increase] vs. 62.8 ± 0.4 kg [0.27% increase], p < 0.049); RTF (SOmaxP: 33.3 ± 1.1 reps
[44.8% increase] vs. 27.8 ± 1.1 reps [20.9% increase], p < 0.004); and fat mass (SOmaxP: 12.06 ± 0.53 kg [9.8%
decrease] vs. 13.90 ± 0.53 kg [4.1% increase], p < 0.024). No statistically significant differences in vital signs (heart
rate, systolic and diastolic blood pressures) or clinical blood chemistries were noted.
Conclusions: These data indicate that compared to CP, SOmaxP administration augments and increases gains in
lean mass, bench press strength, and muscular performance during nine weeks of intense resistance training.
Studies designed to confirm these results and clarify the molecular mechanisms by which SOmaxP exerts the
observed salutary effects have begun. Both SOmaxP and the CP were well-tolerated, and no supplement safety
issues were identified.
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The use of pre- or peri-workout supplements among
recreational and elite athletes have become increasingly
popular due to studies suggesting improvements in
aerobic and anaerobic performance and recommenda-
tions from expert panels in sports nutrition [1]. Among
the most commonly used supplements for increasing
muscular strength are those containing various creatine
salts including creatine monohydrate [2], carbohydrate,
protein [3], and amino acids [4], particularly branched
chain amino acids (BCAA), for which evidence of effec-
tiveness has been consistently seen in published studies
[1]. Numerous studies have assessed the effectiveness of
the individual supplements listed above, and have estab-
lished a range of doses at which the specific supplement
showed demonstrable effects. These studies have helped
to establish minimal/threshold doses at which supple-
ments exert their intended effects. Research data is most
plentiful on supplementation with creatine monohy-
drate, carbohydrates, and protein and these three ingre-
dients are consistently recommended by expert panels
as ergogenic aids, and as such are the core constituent
ingredients of many pre- and peri-workout supplements.
Based on the findings of such research and expert
recommendations, supplement manufacturers have
developed sports drinks combining the same three core
ingredients and have added proprietary ingredients to be
used in the peri-workout time period to increase muscle
strength, lean mass, and/or endurance. Aside from the
convenience of having multiple ingredients in one pro-
duct, there is potential for the components to exert
additive or synergistic effects. Because different dietary
supplement products contain differing quantities of the
core and proprietary components, it is often difficult to
perform valid head-to-head studies. However, because
most products purporting to build strength and/or
endurance contain the same three core ingredients, and
the preponderance of evidence suggests that these three
ingredients are the most important contributors to
observed ergogenic gains, then it is reasonable to
assume that if similar quantities of the core ingredients
were compared, a valid comparison could be made. If
differences were found between two products, then a
likely explanation for the difference would be some
effect of the proprietary ingredients, since the core
ingredients are matched by dose. Proprietary ingredients
could contribute to a difference either by exerting inde-
pendent effects or by enhancing the effects of the core
ingredients in a differential way or both.
Size On Maximum Performance™ (SOmaxP) is a pro-
duct manufactured by Gaspari Nutrition containing
creatine, carbohydrate, whey protein and other proprie-
tary ingredients, and was used during the peri-workout
period only on the days when resistance training occurs.
The comparator product was standardized to contain
similar amounts of creatine, carbohydrate and whey pro-
tein. The study compared the effects of SOmaxP to a
comparator product (CP), which was standardized to
contain equal amounts of creatine (4 g creatine mono-
hydrate), carbohydrate (39 g maltodextrin) and protein
(7 g whey protein hydrolysate), and given with identical
timing. We hypothesized that subjects in the SOmaxP
groups would outperform the subjects in the CP during
post-testing after adjusting for baseline differences.
Methods
Subjects
Twenty subjects, ten in each group, were randomized to
receive either SOmaxP or CP during this 9-week study.
Key elements of the inclusion criteria included: male or
female subject in good health; aged between 18-45; a
body fat of 10%-25% inclusive; who had undergone reg-
ular resistance training for at least two years; who had
signed an informed consent; who were willing and able
to comply with the training and supplement protocol;
possessed normal vital signs; and had a fluent under-
standing of English. Physical activity levels and health
history were determined using standardized question-
naires adapted from Kent State University, Purdue Uni-
versity, and Eastern Michigan University at baseline and
weeks 3, 6 and 9. The protocol was in compliance with
the Helsinki Declaration, and was approved by the Inte-
gReview Ethical Review Board (Austin, TX). Although
the inclusion criteria allowed for female subjects, no
females enrolled in the study. The actual age range of
subjects who participated in the study was 19-31 years.
Key exclusion criteria included: a history of various
metabolic conditions or diseases; the concomitant use of
a variety of medications, including but not limited to
those with androgenic and/or anabolic effects; the use of
nutritional supplements known to improve strength
and/or muscle mass (e.g., creatine, HMB, androstene-
dione, DHEA, etc.) within six weeks prior to the start of
the study; a weight gain or loss of more than 10 lbs.
within the past 30 days; known allergy to any ingredi-
ents in SOmaxP Maximum Performance™ or CP; partici-
pation in other research studies within the last 30 days;
the current use of tobacco products; and the presence
of any orthopedic limitations or injuries.
Study Design
The study was a prospective, randomized, double-blind,
parallel-group clinical trial. Subjects were matched into
two groups according to body mass, age, and resistance
training experience. Subjects were then randomly
assigned (via the ABBA procedure [5]) to receive either
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to the first testing session, a research nutritionist and
Certified Strength and Conditioning Specialist (CSCS)
met with each subject and discussed in detail the
strength training regimen, and nutritional and supple-
ment requirements for the study period.
Testing Sessions
Prior to pre-testing, subjects were instructed to refrain
from heavy exercise for 48 hours and fast for at least 12-
hours. The assessment of upper body muscular strength
(1-RM) and repetitions to failure (RTF) testing was per-
formed after a general warm-up of 3-5 minutes of light
activity involving the muscle(s) to be tested (e.g., upper
body ergometry prior to upper body strength testing).
Next, the subject performed several minutes of static
stretching exercises of the involved musculature. The
subject then performed a specific warm-up set of 8 repe-
titions at approximately 50% of the perceived 1-RM fol-
lowed by another set of 3 repetitions at 70% of the
perceived 1-RM. Subsequent lifts were single repetitions
of progressively heavier weights until failure. The initial
increments in weight were evenly spaced and adjusted
such that at least two single lift sets was performed
between the three repetition warm-up set and the esti-
mated 1-RM. At failure, a weight approximately midway
between the last successful and failed lift was attempted.
This process was repeated until the 1-RM was deter-
mined. The rest interval between sets was between 3-5
minutes (procedure modified from Brown et al., 2001)
[6]. Results were obtained at baseline, and at week 3, 6
and 9. For testing at weeks 3, 6 and 9, in order to repli-
cate pre-supplementation/baseline testing conditions as
closely as possible, subjects were instructed to follow
their previously recorded 3-day diet records, refrain from
heavy exercise for 48 hours, and fast for at least 12-hours
prior to the workout. Upper body muscle endurance was
measured as the total repetitions completed during three
successive sets of isotonic bench press at a load equal to
100% subjects’ pre-testing body weight. Each set was
separated by a one-minute rest period.
Body Composition Assessment
Body composition was assessed at baseline, and weeks 3,
6 and 9. Standing height was determined using a wall-
mounted stadiometer. Body weight was measured using a
SECA™ Medical Scale. Lean mass and fat mass were
assessed using dual energy x-ray absorptiometry (DEXA,
General Electric LUNAR DPX Pro). For each subject, the
same technician performed all four DEXA measurements.
Supplementation Protocol
SOmaxP contains creatine monohydrate (4 g), carbohy-
drate (39 g), and whey protein (7 g), and a number of
proprietary ingredients. Subjects randomized to the
SOmaxP group took 1 serving of SOmaxP + 30 ounces
of water starting 10-15 minutes before the workout and
f i n i s h i n gb e f o r et h ee n do ft h ew o r k o u t ,a n du s e dt h e
product only on the days when resistance training
occurs. The comparator product (CP) was standardized
to contain equal amounts of creatine monohydrate (4 g),
carbohydrate (39 g maltodextrin) and protein (7 g whey
protein), and given with 30 ounces of water, with identi-
cal timing, and similarly used only on resistance training
days. The CP was virtually indistinguishable in taste,
color and consistency to SOmaxP. The supplements
were prepared in powder form and packaged in coded
generic containers for double-blind administration by an
independent company (Command Nutritionals, Fairfield,
NJ). Compliance to the supplementation protocol was
monitored by a research nurse/dietician who contacted
the study subjects on a weekly basis by telephone. Sub-
jects were required to bring in their supplement bottles
on workout days at weeks 3, 6 and 9 for visual inspec-
tion by study personnel to assess compliance with the
protocol.
Side Effect Assessment
A questionnaire was completed at weeks 3, 6 and 9
(workout sessions 12, 24 and 36) to monitor individual
changes in DOMS and assess potential adverse events
and change in sleep habits, general attitude, irritability,
appetite, thirst, muscle soreness, muscle cramping, sto-
mach distress, and headache, as well as any other idio-
syncratic responses to the supplementation/training
protocol. If identified, events were recorded as adverse
events. In addition, subjects were contacted on a weekly
basis by phone contact to inquire if they had experi-
enced any adverse events, and were told to call at any
time during the study to report side effects.
Dietary (Nutrition) Monitoring
The research dietitian met with each subject to explain
the proper procedures for recording dietary intake. Each
subject’s baseline diet (3-days: two weekdays & one
weekend day) was analyzed using the NutraBase IV
Clinical Edition, (CyberSoft, Inc., Phoenix, AZ) to deter-
mine its energy and macronutrient content. Additional
3-day diet records were analyzed at weeks 3, 6 and 9 to
verify that eating habits had remained consistent
throughout the study.
Resistance Training Protocol
All subjects followed a specific 4-day per week workout
designed by a Certified Strength and Conditioning Spe-
cialist (CSCS). The workout involved training the upper
and lower body twice per week using a 4-day split (i.e.,
upper body
1, lower body
1,u p p e rb o d y
2,l o w e rb o d y
2)
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workout consisted of at least 12 exercises, including but
not limited to: bench press, lat pulldown, shoulder
press, seated row, shoulder shrug, dip, biceps curl, tri-
ceps push down, leg press, squat, deadlift, lunge, leg
curl, leg extension, and calf raise. For each exercise, sub-
jects performed 3-6 sets of 8-15 repetitions with as
much weight as they could handle with good form (typi-
cally 70-85% of the 1-repetition maximum). As subject
strength and endurance improved, training resistances
were progressively increased to maintain the required
repetition range. Rest periods between exercises were
1-3 minutes, and between sets were 60-120 seconds.
Training was conducted at the subject’sl o c a lt r a i n i n g
facility, documented in training logs, and signed off by
fitness instructors/gym personnel to verify compliance.
Two different facilities were utilized and identical equip-
ment was available at both facilities. In addition, at each
session, the subject completed a physical activity ques-
tion, which described their physical activity during the
preceding month. A schematic of the training program
is displayed below in Figure 1.
Clinical Laboratory Chemical Analyses
Laboratory measures were performed at baseline, and
weeks 3, 6 and 9. The tests included a complete blood
count (CBC) with differential and platelet count, and a
chemistry panel, which included sodium, potassium,
chloride, carbon dioxide, calcium, AP, AST, ALT, biliru-
bin, glucose, blood urea nitrogen, creatinine, albumin,
globulin, and estimated glomerular filtration rate, The
lipid panel (total cholesterol, HDL- and LDL-cholesterol)
was drawn at baseline and at week 9. Quest Diagnostics
(Pittsburg, PA) was utilized to transport and analyze all
blood samples.
Statistical Analysis
Separate analyses of co-variance (ANCOVA), using
baseline scores as the covariate were used to analyze
between-group differences in body composition, muscu-
lar performance, and clinical markers of safety. Data was
considered statistically significant when the probability
of a type I error was less than or equal to 0.05 (P ≤
0.05). If a significant group, treatment and/or interaction
was observed, least significant differences (LSD) post-
hoc analyses were performed to locate the pair-wise dif-
ferences between means.
Results
Demographics
The demographic characteristics of the two cohorts
were similar, and these are presented in Table 1. All 20
subjects were male, and the age range was 19-31 years.
The mean values for age, height, weight, baseline fat
percentage, blood pressure and resting heart rate were
similar in the two cohorts.
Performance Measures
A summary of the performance and outcome measures
at baseline ("Pre”) and at week 9 session ("Post”)a r e
presented in Table 2 and discussed below. The values
are the mean values per cohort at baseline and week 9.
Figure 2 displays these data using the least square mean
ANCOVA analysis for 1 RM. Figure 3 displays the
ANCOVA for Repititions to Failure (RTF). Figure 4
displays the ANCOVA for percent body fat. Figure 5
displays the ANCOVA for lean mass. Figure 6 displays
the ANCOVA for fat mass. Statistically significant differ-
ences between the SOmaxP and CP cohorts were
observed for 1 RM (p = 0.019), RTF (p = 0.004), body
fat percent (p = 0.028), lean mass (p = 0.049), and fat
mass (p = 0.023).
The measures of muscular performance (1-RM and
RTF total) increased in both the SOmaxP and CP
cohorts, though by a higher percentage in the SOmaxP
group. The 1 RM for the SOmaxP cohort increased
from 233.5-283.5 lbs. [106.1-128.9 kg] from pre- to
post-testing (21.4% increase), while the CP cohort
increased from 256.5-292.5 lbs. [116.6-132.9 kg], (14.0%
increase). The RTF for the SOmaxP cohort increased
from 19.6 to 30.25 from pre- to post-testing (54.3%
increase), while the CP cohort increased from 26.3 to
30.8 (17.1% increase).
Several measures of body composition differed statisti-
cally between the two cohorts, with the SOmaxP cohorts
demonstrating favorable improvements. The body fat
percentage in the SOmaxP group decreased from 16.8%
to 15.5% from pre- to post-testing (7.7% decrease), while
the CP cohort increased slightly from 16.5% to 16.9%
(2.4% increase). Lean body mass increased in the
SOmaxP group from 62.7 kg to 64.2 kg (2.4% increase),
while the CP cohort increased marginally from 62.6 kg
to 62.8 kg (0.3% increase). Body weight did not change
significantly in either group, with the SOmaxP group
experiencing a drop of 1.5 kg from a baseline of 81.1 kg
to 80.8 kg (0.2 kg decrease), while the CP cohort gained
1.5 kg from a baseline of 79.9 kg to 80.2 kg (0.2 kg
increase). Finally, in the SOmaxP cohort, fat mass
decreased from 13.5 kg to 12.2 kg (9.6% decrease), while
the CP cohort increased from 13.3 kg to 13.8 kg (3.8%
increase). The percentage change from baseline (Post
minus Pre × 100) in strength measures (RTF(t) and 1-
RM) are presented in Figure 7 below, and similar
changes in body composition measures (lean mass, body
fat percentage and fat mass) are presented in Figure 8.
There were no clinically meaningful changes in vital
signs or laboratory results from baseline to Week 9.
One subject experienced an adverse event. The subject
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Table 1 Baseline Demographic Characteristics
Parameter SOmaxP 95% CI Comparator (CP) 95% CI
Age (years) 21.9 20.5-23.3 23.9 21.9-25.9
Height (inches) 70.7 69.0-72.4 69.8 68.3-71.3
Weight (kg) 81.1 77.3-84.9 79.9 74.2-85.6
Fat percentage 16.78 14.0-19.6 16.45 13.4-19.5
Resting Heart Rate (bpm) 60.9 56.9-64.9 66.4 59.9-73.0
Blood pressure (mm Hg) 133/76 130-136/70-82 128/79 119-136/74-84
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enced seasonal flu symptoms during Week 8 of
the study. Symptoms included nausea, vomiting, and
decreased appetite, and the events were not assessed as
related to study product. Symptoms were resolved at the
Week 9 post-testing visit. There were no significant
changes in dietary intake for the subjects in either
cohort, based on dietary diary evaluation.
Discussion
This double-blind, comparator study showed that nine
weeks of supplementation with SOmaxP resulted in sta-
tistically significant improvements in muscular perfor-
mance (1-RM and RTF), decreases in body fat and fat
mass, and increases in lean mass, versus a comparator
product matched with similar amounts of creatine, car-
bohydrate and whey protein. Both the SOmaxP and CP
were well-tolerated, and there were no changes in
laboratory measures or vital signs during the study.
There were no adverse events assessed as related to
either product, and no significant changes in body
weight occurred during the study period in either group.
The SOmaxP cohort experienced an increase in
strength and a concomitant increase in lean muscle mass
and loss in body fat, without a significant change in body
weight. These changes are consistent with a desired ana-
bolic effect. Improvements in strength were also noted
with the CP, though significantly less than with SOmaxP.
The dose of creatine in this study (4 g/workout or 16 g/
week) for both the SOmaxP and CP cohorts is lower
than what is recommended by some of the more com-
monly described creatine protocols
1, and yet strength
gains were noted in both the SOmaxP and CP groups.
Typical protocols recommend ingesting approximately
0.3 g/kg/day of creatine monohydrate for 5-7 days as a
loading dose (e.g., 5 g 4 times per day), followed by 3-5
g/day thereafter [7,8]. A few studies have found that a
loading period was not necessary for increasing muscle
creatine (3 g/day for 28 days) [9], or muscle size and
strength (6 g/day for 12 weeks) [10,11]. A loading dose
was not used in this study for either cohort. Data from
the current study show measurable strength gains at a
creatine dose of 16 g/week without a loading dose.
The CP cohort gained strength, but only had a slight
increase in lean mass, body fat % and body weight. A
possible explanation for this is that the CP group, taking
Table 2 Summary of Important Outcome Measures from Baseline to Week 9 (Workout session 36)
Measure SOmaxP CP P-Value (ANCOVA)
Baseline Week 9 %Change Baseline Week 9 %Change p-value (difference)*
1-RM lbs (kg) 233.5 (106.1) 283.5 (128.9) 21.4% 256.5 (116.6) 292.5 (132.9) 14.0% 0.019
RTF (total)** 19.6 30.25 54.3% 26.3 30.8 17.1% 0.004
Body Fat % 16.8 15.5 -7.7% 16.5 16.9 2.4% 0.028
Lean Mass (kg) 62.7 64.2 2.4% 62.6 62.8 0.3% 0.049
Body Weight (kg) 81.1 80.8 -0.2% 79.9 80.2 0.2% 0.22
Fat Mass (kg) 13.5 12.2 -9.6% 13.3 13.8 3.8% 0.023
*Via ANCOVA
**RTF (total) represents a sum of the 3 sets of bench press
Figure 2 ANCOVA for 1 Repetition Maximum Bench Press
(1 RM). Figure 3 ANCOVA for Repetitions to Failure (RTF).
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enced physiologic changes sufficient to increase
strength, but not sufficient to measurably increase lean
mass. This finding is consistent with work by Rawson
et al. (2010), who found that subjects who received low
dose creatine (2.3 g/day or 16.1 g/week) for six weeks,
experienced a significant increase in plasma creatine,
and statistically significant enhanced fatigue resistance
without weight gain compared to a matched placebo
group [12].
There are several possible explanations for the statisti-
cally significant difference between the SOmaxP group
and CP, and these may be explained in part by several
of the proprietary ingredients. SOmaxP contains a large
quantity of branched chain amino acids. Branched chain
amino acids (BCAAs), particularly leucine, have been
shown to have anabolic effects, presumably through
reducing protein breakdown [13]. BCAAs have also
been shown to increase the lactate threshold during an
incremental exercise test in trained individuals [14].
Blood lactate concentrations increase significantly dur-
ing intense exercise as anaerobic glycolysis becomes the
dominant energy pathway [15]. In addition, the com-
bined ingestion of protein and leucine with carbohydrate
has been shown to increase post exercise muscle protein
in male subjects [16]. BCAAs also activate key enzymes
in protein synthesis [17], and act in a synergistic fashion
with insulin to allow skeletal muscle to coordinate pro-
tein synthesis [18].
In addition, SOmaxP contains isomaltulose (palati-
nose) as part of its carbohydrate moiety. This carbohy-
drate is present in honey and has been associated with
delayed digestion and absorption, which may account
for the difference in body fat changes between the
SOmaxP group and the CP group. Oizumi and collea-
gues (2007) developed a palatinose-based balanced for-
mula (PBF) for use in human subjects with impaired
glucose tolerance [19]. During a 12-week cross-over
study of dietary intervention in 23 subjects with
Figure 4 ANCOVA for Percent Body Fat.
Figure 5 ANCOVA for Lean Mass.
Figure 6 ANCOVA for Fat Mass.
Figure 7 Percentage Change from Baseline (Post minus Pre ×
100) in Strength Measures.
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250 kcal can of PBF once per day had beneficial effects
on serum free fatty acid levels and visceral fat area.
Visceral fat area decreased by 17.1% in the PBF period
compared to 5.1% in the control period. Abdominal fat
area decreased by 7.7% in the PBF interval while gaining
3.7% in the control period. Free fatty acids decreased by
22% in the PBF intervention, while increasing by 18.7%
during the control period, and the 2-hour post-prandial
glucose level decreased by 15.7% in the PBF intervention
group while increasing by 0.8% in the control period. A
possible mechanism for this finding was described in an
animal study by Matsuo et al. (2007), who found that a
palatinose-based liquid formula suppressed postprandial
glucose level and reduced visceral fat accumulation
compared to a standard formula [20]. These data sug-
gest that palatinose-based carbohydrates may have bene-
ficial effects on fatty acid and glucose metabolism.
In addition, Achten et al. (2007) compared the oxida-
tion rates from orally ingested sucrose and palatinose
(250 kcal) during moderately intense exercise [21].
The authors found that in trained athletes cycling for
150 minutes at approximately 60% of VO2 max experi-
enced significantly lower oxygen consumption with pala-
tinose compared to sucrose, resulting in a lower plasma
insulin response at 30 minutes compared to sucrose.
Subjects consumed either water or 1 of 2 carbohydrate
solutions (sucrose or isomaltulose) providing 1.1 g/min
of carbohydrate. The authors concluded that the lower
carbohydrate delivery and a small difference in plasma
insulin may have resulted in a higher endogenous carbo-
hydrate use and higher fat oxidation during the isomaltu-
lose trial than during the sucrose trial.
Another possible ingredient the SOmaxP that may
contribute to the results of this study is L-ornithine-L-
aspartate (LOLA), a substance shown to be effective in
lowering blood ammonia concentration, particularly in
patients with hepatic encephalopathy [22]. LOLA was
administered at a dose of 20 g/day dissolved in 250 mL
of 5% fructose solution and infused intravenously for a
period of 4 hours during 7 consecutive days with a
superimposed protein load at the end of the daily treat-
ment period. Treatment was associated with a signifi-
cant decrease in cerebral ammonia levels, which have
been shown to be increased in subjects undergoing pro-
longed exercise [23]. Secher and colleagues (2008)
reviewed the changes in cerebral blood flow and meta-
bolism, and suggested that ammonia accumulation
played a likely role in the development of what is
known as central fatigue [24]. The efficacy of both oral
and parenteral LOLA was confirmed by randomized,
placebo-controlled, double-blind studies in patients with
manifest hepatic encephalopathy and hyperammonemia
[25]. The drug was able to reduce high blood ammonia
levels induced either by ammonium chloride or protein
ingestion or existing as a clinical complication of cirrho-
sis per se. Furthermore, LOLA improved performance in
Number Connection Test-A as well as mental state gra-
dation in patients with more advanced hepatic encepha-
lopathy. Stauch et al (1998) found an improvement in
cerebral ammonia levels compared to placebo using an
oral dose of 6 gm per day [26].
In another published trial, LOLA decreased protein
breakdown and stimulated protein synthesis in muscle
in patients with hepatic encephalopathy [27]. The ther-
apy had minimal side effects, increasing with higher
intravenously administered dosages, and was well-
tolerated after oral and parenteral administration. It is
unclear if these results are generalizable to a healthy
population, but the encephalopathy studies show that
LOLA clearly has beneficial effects on the central ner-
vous system and could possibly have an effect on cen-
tral fatigue.
We acknowledge some limitations to the study. No
females enrolled in the study, although some were
approached for possible inclusion. The study group was
small and homogenous, with a relatively tight age range,
on the younger side of the eligibility criteria. No
attempts were made to identify the physiologic mechan-
ism for any differences between the two groups. The
study attempted to control for the use of other supple-
ments during the study, but did not perform any testing
to verify non-use of other supplements.
Conclusions
The use of SOmaxP four times per week for nine weeks
resulted in statistically significant improvements in
strength, muscle endurance, lean muscle mass, and per-
centage body fat versus a comparator with identical
quantities of creatine, whey protein and carbohydrate.
Given that the quantities of the core components were
identical, and these components are presumed to
Figure 8 Percentage Change from Baseline (Post minus Pre ×
100) in Body Composition Measures.
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between the SOmaxP and CP groups may be due to
additive or synergistic effects of the proprietary ingredi-
ents in SOmaxP. Additional research is needed to
further elucidate these effects. A double-blinded, com-
parator controlled study of six weeks duration which
includes muscle biopsy measurements is currently
underway to examine and possibly help identify genetic
and pharmacological mechanisms by which SOmaxP
may exert these effects.
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